在携带BRCA2突变的前列腺癌中，放疗或顺铂治疗的治疗比率得以维持。
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.
作者信息
Vesprini Danny, Narod Steven A, Trachtenberg John, Crook Juanita, Jalali Farid, Preiner John, Sridhar Srikala, Bristow Robert G
机构信息
Department of Radiation Oncology, University of Toronto, Toronto, ON; Sunnybrook Odette Cancer Centre, Toronto, ON;
出版信息
Can Urol Assoc J. 2011 Apr;5(2):E31-5. doi: 10.5489/cuaj.10080.
Abstract
Prostate cancers in patients with a mutation in BRCA2 have earlier disease onset and an aggressive course, often necessitating the use of systemic therapy. However, these tumours are DNA repair-defective and could respond favourably to Parp inhibitors or DNA-damaging agents, depending on the therapeutic ratio (ratio of tumour response to normal tissue toxicity). We describe 3 patients treated with precision radiotherapy or cisplatin who responded favourably to both agents, yet did not suffer undue toxicity. We review the concept of treating such patients with agents that are selectively toxic to repair-deficient tumours.
摘要
携带BRCA2基因突变的前列腺癌患者发病更早，病程侵袭性强，常需进行全身治疗。然而，这些肿瘤存在DNA修复缺陷，根据治疗指数（肿瘤反应与正常组织毒性的比值），可能对聚（ADP-核糖）聚合酶（Parp）抑制剂或DNA损伤剂有良好反应。我们描述了3例接受精确放疗或顺铂治疗的患者，他们对这两种药物均有良好反应，且未出现过度毒性。我们回顾了用对修复缺陷肿瘤具有选择性毒性的药物治疗此类患者的概念。
相似文献
1
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.在携带BRCA2突变的前列腺癌中，放疗或顺铂治疗的治疗比率得以维持。
Can Urol Assoc J. 2011 Apr;5(2):E31-5. doi: 10.5489/cuaj.10080.
2
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.利用癌症的致命弱点：聚（ADP - 核糖）聚合酶抑制剂在BRCA2缺陷型癌症中的治疗潜力
Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.
3
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.6-硫鸟嘌呤选择性杀伤 BRCA2 缺陷型肿瘤并克服 PARP 抑制剂耐药性。
Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14.
4
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.E2F7 的缺失赋予了 BRCA2 缺陷细胞对聚 ADP-核糖聚合酶（PARP）抑制剂的耐药性。
Nucleic Acids Res. 2018 Sep 28;46(17):8898-8907. doi: 10.1093/nar/gky657.
5
Therapeutic targeting and patient selection for cancers with homologous recombination defects.针对具有同源重组缺陷的癌症的治疗靶向和患者选择
Expert Opin Drug Discov. 2017 Jun;12(6):565-581. doi: 10.1080/17460441.2017.1322061. Epub 2017 May 2.
6
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report.顺铂对伴有BRCA2突变的转移性去势抵抗性前列腺癌的疗效：一例报告。
Urol Case Rep. 2021 May 17;38:101712. doi: 10.1016/j.eucr.2021.101712. eCollection 2021 Sep.
7
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.临床多聚（ADP-核糖）聚合酶抑制剂奥拉帕利的预防性窗治疗可延迟 BRCA1 缺陷型小鼠的乳腺肿瘤形成。
J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.
8
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.AZD2281和顺铂对BRCA2缺陷型乳腺肿瘤细胞生长的选择性抑制作用。
Clin Cancer Res. 2008 Jun 15;14(12):3916-25. doi: 10.1158/1078-0432.CCR-07-4953.
9
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.DNA 修复基因改变与转移性去势抵抗性前列腺癌患者对 PARP 抑制剂的反应。
J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.
10
The potential of PARP inhibitors in genetic breast and ovarian cancers.聚（ADP-核糖）聚合酶抑制剂在遗传性乳腺癌和卵巢癌中的潜力。
Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.
引用本文的文献
1
Patient-derived xenografts and organoids model therapy response in prostate cancer.患者来源的异种移植瘤和类器官可模拟前列腺癌的治疗反应。
Nat Commun. 2021 Feb 18;12(1):1117. doi: 10.1038/s41467-021-21300-6.
2
Role of TG2 and TGF-β in the pathogenesis of human breast cancer.转谷氨酰胺酶2（TG2）和转化生长因子-β（TGF-β）在人类乳腺癌发病机制中的作用。
Oncol Lett. 2020 Nov;20(5):221. doi: 10.3892/ol.2020.12057. Epub 2020 Sep 10.
3
Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.一名携带种系BRCA2突变的胰腺癌患者发生放射性结肠炎：病例报告
Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
4
Cytotoxic and targeted therapy for hereditary cancers.遗传性癌症的细胞毒性和靶向治疗
Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016.
5
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.同源重组参与顺铂与聚（ADP-核糖）聚合酶抑制协同作用。
Cancer Sci. 2013 Dec;104(12):1593-9. doi: 10.1111/cas.12281. Epub 2013 Oct 10.
6
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.前列腺癌细胞中 PTEN 的缺失与 RAD51 功能的丧失无关：对放疗和化疗的影响。
Clin Cancer Res. 2012 Feb 15;18(4):1015-27. doi: 10.1158/1078-0432.CCR-11-2189. Epub 2011 Nov 23.
7
Drug therapy for hereditary cancers.遗传性癌症的药物治疗
Hered Cancer Clin Pract. 2011 Aug 6;9(1):5. doi: 10.1186/1897-4287-9-5.
本文引用的文献
1
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.一个涉及 DNA 修复的基因的小干扰 RNA 筛选，鉴定了 POLQ 敲低导致肿瘤特异性放射增敏。
Cancer Res. 2010 Apr 1;70(7):2984-93. doi: 10.1158/0008-5472.CAN-09-4040. Epub 2010 Mar 16.
2
Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay.应用 G2 检测评估携带 BRCA1/BRCA2 突变的女性的染色体辐射敏感性增加。
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1199-205. doi: 10.1016/j.ijrobp.2009.10.020.
3
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.前列腺癌中的雄激素剥夺疗法与心血管风险：美国心脏协会、美国癌症协会和美国泌尿外科学会的科学咨询意见：得到美国放射肿瘤学会认可
Circulation. 2010 Feb 16;121(6):833-40. doi: 10.1161/CIRCULATIONAHA.109.192695. Epub 2010 Feb 1.
4
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo.在小鼠皮肤中，晚期残留的 γ-H2AX 焦点具有剂量反应性，并可预测体内放射敏感性。
Radiat Res. 2010 Jan;173(1):1-9. doi: 10.1667/RR1851.1.
5
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.高通量药物筛选鉴定出针对 BRCA2 缺陷型肿瘤具有特异性毒性的化合物。
Clin Cancer Res. 2010 Jan 1;16(1):99-108. doi: 10.1158/1078-0432.CCR-09-2434. Epub 2009 Dec 15.
6
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.雄激素剥夺治疗期间的糖尿病和心血管疾病：前列腺癌退伍军人的观察性研究。
J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7.
7
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.聚（ADP-核糖）聚合酶抑制剂在癌症治疗中的应用：临床视角。
Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021.
8
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.对携带BRCA突变的肿瘤中聚（ADP - 核糖）聚合酶的抑制作用。
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
9
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.BRCA1调节人乳腺癌细胞中的恶性细胞行为、生存素表达及化学敏感性。
Int J Cancer. 2009 Dec 15;125(12):2820-8. doi: 10.1002/ijc.24684.
10
Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.BRCA1功能缺失增强顺铂在体内对人乳腺癌异种移植瘤的抗肿瘤活性。
Cancer Biol Ther. 2009 Apr;8(7):648-53. doi: 10.4161/cbt.8.7.7968. Epub 2009 Apr 28.
Zotero 插件